Anti-CEmX monoclonal antibody (Fountain Biopharma)

N/A

Report date: 2022/07/11 10:04:45

Base Information

Drug NameAnti-CEmX monoclonal antibody (Fountain Biopharma)
Drug Alias Nameh4B12FB-825
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsApoptosis stimulantsAnti-IgE
TargetsImmunoglobulin E
Therapy Area/IndicationsDermatitis, AtopicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAcademia Sinica
China Registration ClassN/A

Develop Information

Active CompaniesOneness Biotech Co LtdLeo Pharma A/SMicrobio(shanghai) Co Ltd
Inactive CompaniesFountain Biopharma Inc
Active IndicationsDermatitis, AtopicAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A